As-Needed Versus Regular Intranasal Corticosteroid Therapy in Pediatric Perennial Allergic Rhinitis: A Randomized

Supaluk Chatmaitri1, Ongon Boonnijasin1, Apiradee Wisitsartkul2

  • 1Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Insights

Regular intranasal corticosteroid (INCS) use showed early benefits for pediatric perennial allergic rhinitis (PAR) symptom control compared to as-needed use. However, these clinical advantages diminished over time, suggesting as-needed INCS may be a viable alternative for some patients.

Area of Science:

  • Pediatric Allergy and Immunology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Intranasal corticosteroids (INCS) are the primary treatment for allergic rhinitis (AR).
  • Daily adherence to INCS can be challenging for pediatric patients.
  • Limited evidence exists comparing regular versus as-needed INCS for pediatric perennial allergic rhinitis (PAR).

Purpose of the Study:

  • To assess the efficacy and safety of regular versus as-needed INCS in children with PAR.
  • To evaluate the anti-inflammatory effects of different INCS dosing strategies.
  • To compare symptom scores, quality of life, and nasal cytology between treatment groups.

Main Methods:

  • An 8-week, randomized, double-blind, double-dummy trial involving 70 children (aged 6-18) with PAR.
  • Participants were assigned to regular or as-needed intranasal fluticasone furoate.
  • Outcomes included symptom scores, visual analog scales, quality of life, nasal cytology, and adverse events.

Main Results:

  • Regular INCS showed superior early improvements in total, nasal, and ocular symptom scores and nasal airflow compared to as-needed use.
  • These early clinical differences were not sustained by week 8.
  • Regular INCS led to greater reductions in nasal eosinophils and basophilic cells, while as-needed use resulted in lower cumulative INCS exposure.
  • Adverse events were similar, with epistaxis noted only in the as-needed group.

Conclusions:

  • Regular INCS use provides initial clinical and anti-inflammatory benefits over as-needed use in pediatric PAR.
  • The clinical benefits of regular INCS did not persist throughout the 8-week study period.
  • As-needed INCS demonstrated symptom improvement from baseline and may be a suitable alternative for symptom management in select pediatric PAR patients.
Abstract

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Epistaxis01:30

Epistaxis

Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...